This session will delve into the latest advancements and strategic insights shaping the development of high concentration monoclonal antibody (mAb) formulations. With the growing demand for subcutaneous delivery and patient-centric biologics, formulation scientists are increasingly challenged to design stable, manufacturable, and patient-friendly high-concentration mAb products. Experts from industry and academia will explore emerging technologies, formulation strategies, excipient innovations, and analytical approaches that address viscosity, stability, and delivery challenges. The session will also highlight regulatory considerations and future directions, offering a comprehensive outlook on where the field is heading in the next decade.

Sanjeev Gupta

Sr. Vice President - Advanced Biotech Lab

Ipca Laboratories Ltd.